NASDAQ: VOR
Vor Biopharma Inc.
Healthcare · Biotechnology
After hours: $23.50(-0.72%) · as of 7:48 PM ET
Per-share valuation inputs need verification
Event dated Mar 31, 2026Market-derived shares outstanding and recent statement shares differ materially. Per-share ratios and valuation outputs may be unreliable until the share base is verified. This sometimes appears with ADRs or provider share-count gaps.
Market Cap
$1.28B
52w High
$50.20
52w Low
$6.50
P/E
-0.04
Volume
801.80K
Outstanding Shares
54.19M
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock fell 42.83% over the last year. Free cash flow declined 49.74% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Free cash flow fell 49.74% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer.
Valuation
Stock splits
Every 20 shares became 1
Profitability & growth
Analyst consensus
10
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 11, 2026
Q3 FY26 · EPS est -$0.70 · Revenue est —
View